Zevra Therapeutics logo

Zevra Therapeutics Share Price Today

(NASDAQ: ZVRA)

Zevra Therapeutics share price is $7.7 & ₹670.40 as on 6 Mar 2025, 2.30 'hrs' IST

$7.7

0.31

(4.19%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Zevra Therapeutics share price in Dollar and Rupees. Guide to invest in Zevra Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Zevra Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Zevra Therapeutics share price movements

  • Today's Low: $7.33
    Today's High: $7.72

    Day's Volatility :5.05%

  • 52 Weeks Low: $4.20
    52 Weeks High: $9.76

    52 Weeks Volatility :56.97%

Zevra Therapeutics (ZVRA) Returns

PeriodZevra Therapeutics IncIndex (Russel 2000)
3 Months
-14.4%
0.0%
6 Months
6.5%
0.0%
1 Year
23.2%
0.0%
3 Years
41.03%
-11.6%

Zevra Therapeutics (ZVRA) Key Statistics

in dollars & INR

Previous Close
$7.39
Open
$7.38
Today's High
$7.72
Today's Low
$7.33
Market Capitalization
$394.4M
Today's Volume
$288.8K
52 Week High
$9.76
52 Week Low
$4.2
Revenue TTM
$24.5M
EBITDA
$-81.2M
Earnings Per Share (EPS)
$-2.14
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-130.67%

How to invest in Zevra Therapeutics Stock (ZVRA) from India?

It is very easy for Indian residents to invest directly in Zevra Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Zevra Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Zevra Therapeutics or ZVRA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Zevra Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Zevra Therapeutics shares which would translate to 0.113 fractional shares of Zevra Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Zevra Therapeutics, in just a few clicks!

Returns in Zevra Therapeutics (ZVRA) for Indian investors in Rupees

The Zevra Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Zevra Therapeutics investment value today

Current value as on today

₹1,28,265

Returns

₹28,265

(+28.26%)

Returns from Zevra Therapeutics Stock

₹23,200 (+23.2%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Zevra Therapeutics (ZVRA)

14%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Zevra Therapeutics Stock from India on INDmoney has increased by 14% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Zevra Therapeutics

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Zevra Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Zevra Therapeutics Stock (ZVRA)

What analysts predicted

Upside of 169.48%

Target:

$20.75

Current:

$7.70

Insights on Zevra Therapeutics Stock (Ticker Symbol: ZVRA)

  • Price Movement

    In the last 3 years, ZVRA stock has moved up by 46.4%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 4.44M → 3.69M (in $), with an average decrease of 17.0% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -5.08M → -33.22M (in $), with an average decrease of 70.3% per quarter
  • ZVRA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 43.3%
  • ZVRA vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 5.2%
  • Price to Sales

    ForZVRA every $1 of sales, investors are willing to pay $13.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

ZVRA Zevra Therapeutics Financials in INR & Dollars

FY19Y/Y Change
Revenue
$12.8M
-
Net Income
$-24.5M
↓ 56.57%
Net Profit Margin
-191.0%
-
FY20Y/Y Change
Revenue
$13.3M
↑ 3.5%
Net Income
$-12.8M
↓ 47.97%
Net Profit Margin
-96.03%
↑ 94.97%
FY21Y/Y Change
Revenue
$28.7M
↑ 115.61%
Net Income
$-8.6M
↓ 32.95%
Net Profit Margin
-29.86%
↑ 66.17%
FY22Y/Y Change
Revenue
$10.5M
↓ 63.5%
Net Income
$-41.5M
↑ 385.6%
Net Profit Margin
-397.24%
↓ 367.38%
FY23Y/Y Change
Revenue
$27.5M
↑ 162.58%
Net Income
$-46.0M
↑ 10.85%
Net Profit Margin
-167.69%
↑ 229.55%
Q1 FY23Q/Q Change
Revenue
$2.9M
↑ 24.15%
Net Income
$-11.8M
↑ 30.44%
Net Profit Margin
-408.72%
↓ 19.72%
Q2 FY23Q/Q Change
Revenue
$8.5M
↑ 194.2%
Net Income
$-5.1M
↓ 56.79%
Net Profit Margin
-60.02%
↑ 348.7%
Q3 FY23Q/Q Change
Revenue
$2.9M
↓ 65.82%
Net Income
$-14.0M
↑ 176.26%
Net Profit Margin
-485.15%
↓ 425.13%
Q1 FY24Q/Q Change
Revenue
$3.4M
↑ 18.31%
Net Income
$-16.6M
↑ 18.35%
Net Profit Margin
-485.31%
↓ 0.16%
Q2 FY24Q/Q Change
Revenue
$4.4M
↑ 29.9%
Net Income
$-19.9M
↑ 19.87%
Net Profit Margin
-447.85%
↑ 37.46%
Q3 FY24Q/Q Change
Revenue
$3.7M
↓ 16.95%
Net Income
$-33.2M
↑ 66.75%
Net Profit Margin
-899.19%
↓ 451.34%
FY18Y/Y Change
Profit
$-324.0K
↓ 3.57%
FY19Y/Y Change
Profit
$9.9M
↓ 3153.7%
FY20Y/Y Change
Profit
$12.0M
↑ 21.11%
FY21Y/Y Change
Profit
$26.6M
↑ 121.91%
FY22Y/Y Change
Profit
$10.1M
↓ 61.96%
FY23Y/Y Change
Profit
$24.5M
↑ 142.37%
Q1 FY23Q/Q Change
Profit
$2.8M
↑ 26.56%
Q2 FY23Q/Q Change
Profit
$7.8M
↑ 182.97%
Q3 FY23Q/Q Change
Profit
$2.8M
↓ 64.7%
Q1 FY24Q/Q Change
Profit
$160.0K
↓ 94.18%
Q2 FY24Q/Q Change
Profit
$876.0K
↑ 447.5%
Q3 FY24Q/Q Change
Profit
$1.4M
↑ 58.9%
FY19Y/Y Change
Operating Cash Flow
$-23.7M
↓ 56.21%
Investing Cash Flow
$3.2M
-
Financing Cash Flow
$4.9M
↓ 82.37%
FY20Y/Y Change
Operating Cash Flow
$-1.9M
↓ 91.83%
Investing Cash Flow
$-33.0K
↓ 101.02%
Financing Cash Flow
$2.7M
↓ 44.54%
FY21Y/Y Change
Operating Cash Flow
$10.4M
↓ 638.37%
Investing Cash Flow
$-15.5M
↑ 46942.42%
Financing Cash Flow
$113.1M
↑ 4029.57%
FY22Y/Y Change
Operating Cash Flow
$-18.7M
↓ 279.3%
Investing Cash Flow
$-36.7M
↑ 136.53%
Financing Cash Flow
$8.4M
↓ 92.62%
Q1 FY23Q/Q Change
Operating Cash Flow
$-4.0M
↓ 9.35%
Investing Cash Flow
$-17.6M
↑ 27765.08%
Financing Cash Flow
$-3.8M
↑ 1359.14%

Zevra Therapeutics Technicals Summary

Sell

Neutral

Buy

Zevra Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Zevra Therapeutics (ZVRA) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zevra Therapeutics Inc logo
-5.29%
6.5%
23.2%
41.03%
91.81%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zevra Therapeutics Inc logo
NA
NA
10.67
-1.93
-1.31
-0.33
NA
1.31
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zevra Therapeutics Inc logo
Buy
$394.4M
91.81%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Organization
Zevra Therapeutics
Employees
65
CEO
Mr. Neil F. McFarlane
Industry
Miscellaneous

Management People of Zevra Therapeutics

NameTitle
Mr. Neil F. McFarlane
President, CEO & Director
Mr. R. LaDuane Clifton CPA
CFO, Secretary & Treasurer
Mr. Joshua M. Schafer M.B.A.
Chief Commercial Officer & Executive VP of Business Development
Ms. Nichol L. Ochsner
Vice President of Investor Relations & Corporate Communications
Mr. Rahsaan W. Thompson J.D.
Chief Legal Officer, Secretary & Compliance Officer
Ms. Alison Peters
Chief People Officer
Dr. Christopher M. Lauderback Ph.D.
Senior Vice President of Manufacturing
Dr. Rene A. Braeckman Ph.D.
Senior Vice President of Clinical Development
Dr. Daniel Gallo Ph.D.
Senior Vice President of Medical Affairs & Advocacy
Dr. Adrian Quartel FFPM, M.D.
Chief Medical Officer

Important FAQs about investing in ZVRA Stock from India :

What is Zevra Therapeutics share price today?

Zevra Therapeutics share price today stands at $7.70, Open: $7.38 ; Previous Close: $7.39 ; High: $7.72 ; Low: $7.33 ; 52 Week High: $9.76 ; 52 Week Low: $4.20.

The stock opens at $7.38, after a previous close of $7.39. The stock reached a daily high of $7.72 and a low of $7.33, with a 52-week high of $9.76 and a 52-week low of $4.20.

Can Indians buy Zevra Therapeutics shares?

Yes, Indians can invest in the Zevra Therapeutics (ZVRA) from India.

With INDmoney, you can buy Zevra Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Zevra Therapeutics at zero transaction cost.

How can I buy Zevra Therapeutics shares from India?

It is very easy to buy Zevra Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Zevra Therapeutics (ZVRA) be purchased?

Yes, you can buy fractional shares of Zevra Therapeutics with INDmoney app.

What are the documents required to start investing in Zevra Therapeutics stocks?

To start investing in Zevra Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Zevra Therapeutics Stock (ZVRA)?

Today’s highest price of Zevra Therapeutics (ZVRA) is $7.72.

Today’s lowest price of Zevra Therapeutics (ZVRA) is $7.33.

What is today's market capitalisation of Zevra Therapeutics?

Today's market capitalisation of Zevra Therapeutics ZVRA is 394.4M

What is the 52 Week High and Low Range of Zevra Therapeutics Stock (ZVRA)?

  • 52 Week High

    $9.76

  • 52 Week Low

    $4.20

What are the historical returns of Zevra Therapeutics (ZVRA)?

  • 1 Month Returns

    -5.29%

  • 3 Months Returns

    6.5%

  • 1 Year Returns

    23.2%

  • 5 Years Returns

    91.81%

Who is the Chief Executive Officer (CEO) of Zevra Therapeutics ?

Mr. Neil F. McFarlane is the current Chief Executive Officer (CEO) of Zevra Therapeutics.